Jewel Sawyer
Medical · Marietta, GANPI 1528346152
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,655 of the $73,782 with a category attached, or 78.1%. Janssen Scientific Affairs, LLC accounts for 88.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $37,964 and has fallen 94.0% since, to $2,262 in 2025. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $157.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$65K
- Viiv Healthcare Company$3K
- Gilead$3K
- Merck$775
- Theratechnologies Inc.$456
- Johnson & Johnson$326
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$57,65578%
- Travel & lodging$7,17010%
- Food & beverage$8,91212%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 59 | $65,350 |
| Viiv Healthcare Company | 140 | $2,806 |
| Gilead | 110 | $2,707 |
| Merck | 37 | $775 |
| Theratechnologies Inc. | 24 | $456 |
| Johnson & Johnson | 24 | $326 |
| EMD Serono, Inc. | 21 | $314 |
| Lilly USA, LLC | 13 | $260 |
| AbbVie | 11 | $235 |
| Novo Nordisk | 9 | $162 |
| Verity Pharmaceuticals Inc. | 5 | $83 |
| Antares Pharma, Inc. | 3 | $56 |
| Janssen Products, LP | 1 | $45 |
| Napo Pharmaceuticals Inc | 2 | $38 |
| Dexcom, Inc. | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,782 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 113 | $442,137 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 40 | $236,110 |
| CabenuvaCabotegravir/Rilpivirine | 30 | $176,268 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 43 | $166,880 |
| PrezcobixDarunavir/Cobicistat | 49 | $117,190 |
| TivicayDolutegravir Sodium | 51 | $114,095 |
| JulucaDolutegravir/Rilpivirine | 17 | $81,628 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $49,317 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $31,415 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $30,666 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 18 | $5,476 |
| AbacavirAbacavir Sulfate | 19 | $4,563 |
| Lamivudine | 25 | $2,455 |
| Estradiol Valerate | 12 | $1,625 |
| Testosterone Cypionate | 39 | $1,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $2,707 | $639,683171 claims |
| Viiv Healthcare CompanyCabenuva, Tivicay, Juluca, Triumeq, Dovato | $2,806 | $452,723124 claims |
| Janssen Products, LPSymtuza | $45 | $236,11040 claims |
| Johnson & JohnsonPrezcobix | $326 | $117,19049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.
Other medical in Marietta
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Sarah MillerMarietta$10K
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.